Combination of mglur2 antagonist and ache inhibitor for...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/551 (2006.01) A61K 31/4535 (2006.01) A61K 31/473 (2006.01) A61K 31/55 (2006.01) A61K 31/662 (2006.01) A61K 31/7068 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2532347

The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.

La présente invention concerne une technique de traitement ou de prévention de troubles neurologiques aigus et/ou chroniques, une composition pharmaceutique comprenant un inhibiteur d'acétylcholinesterase (inhibiteur AchE) et un antagoniste du récepteur 2 de glutamate métabotropique (antagoniste mGluR2), l'utilisation d'un inhibiteur AChE et d'un antagoniste mGluR2 dans la préparation d'un médicament et, des kits comprenant un inhibiteur AChE et un antagoniste mGluR2.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combination of mglur2 antagonist and ache inhibitor for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination of mglur2 antagonist and ache inhibitor for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of mglur2 antagonist and ache inhibitor for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1888544

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.